Research programme: obesity therapy - LG Life Sciences

Drug Profile

Research programme: obesity therapy - LG Life Sciences

Alternative Names: LB-53280

Latest Information Update: 07 Oct 2015

Price : $50

At a glance

  • Originator LG Life Sciences
  • Developer LG Life Sciences; Takeda
  • Class
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 28 Aug 2015 Preclinical trials in Obesity in China (PO)
  • 22 Oct 2014 Preclinical development is ongoing in South Korea
  • 20 Jul 2012 Preclinical development is ongoing in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top